SPINK11 Inhibitors
SPINK11 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of SPINK11 (Serine Protease Inhibitor Kazal Type 11), a protein that is part of the serpin family of serine protease inhibitors. SPINK11 is primarily expressed in tissues such as the pancreas and plays a significant role in regulating proteolytic activity by inhibiting serine proteases. These enzymes are involved in various biological processes, including digestion, immune response, and tissue remodeling. By controlling the activity of serine proteases, SPINK11 helps maintain the balance of protein degradation and synthesis, preventing excessive proteolytic activity that could lead to tissue damage or pathological conditions.
The mechanism of action of SPINK11 inhibitors typically involves binding to specific regions of the SPINK11 protein, particularly its reactive center loop, which is critical for its interaction with serine proteases. Inhibitors may compete with serine proteases for binding, blocking the formation of enzyme-inhibitor complexes, or they may induce conformational changes in SPINK11 that impair its ability to inhibit proteases effectively. By inhibiting SPINK11, these compounds can disrupt the regulation of proteolytic activity, potentially leading to increased protease function and downstream effects on cellular processes such as apoptosis, inflammation, and repair mechanisms. Research into SPINK11 inhibitors provides valuable insights into the complex regulatory networks governing protease activity and highlights the essential role of serine protease inhibitors in maintaining cellular homeostasis. Understanding how SPINK11 operates and how its inhibition affects protease regulation contributes to a broader understanding of the molecular dynamics that underpin various physiological processes and cellular functions.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. SPINK11 is potentially regulated during the cell cycle, and by inhibiting CDK4/6, palbociclib may indirectly lead to altered cell cycle progression, affecting SPINK11's activity or expression if it is cell cycle-dependent. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K). PI3K signaling is crucial for many cellular processes, including growth and survival. By inhibiting PI3K, LY294002 could indirectly affect SPINK11 expression or function by altering the cellular context in which SPINK11 operates. | ||||||
Trichostatin A | 58880-19-6 | sc-3511 sc-3511A sc-3511B sc-3511C sc-3511D | 1 mg 5 mg 10 mg 25 mg 50 mg | $149.00 $470.00 $620.00 $1199.00 $2090.00 | 33 | |
Trichostatin A is a histone deacetylase inhibitor. Changes in histone acetylation status can result in altered gene expression. By inhibiting HDACs, Trichostatin A could potentially affect the expression level of SPINK11 by altering chromatin structure. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor that can suppress cell growth and proliferation. As SPINK11 may be involved in cellular processes that are influenced by mTOR signaling, rapamycin could indirectly decrease SPINK11 activity by altering the mTOR pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which are upstream of ERK in the MAPK pathway. Since the MAPK pathway regulates various cellular functions, U0126 could indirectly affect SPINK11 expression or activity by inhibiting MEK1/2 and thus altering MAPK pathway signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. The p38 MAPK pathway is implicated in stress response and inflammation. Inhibiting p38 with SB203580 could indirectly influence SPINK11's role in the cellular response to stress or inflammatory signals. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. By inhibiting EGFR signaling, gefitinib can affect numerous downstream signaling pathways. SPINK11 could be indirectly influenced by changes in these pathways due to EGFR inhibition. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is a proteasome inhibitor. It prevents the degradation of proteins, which can lead to cell cycle arrest and apoptosis. If SPINK11 is affected by proteasome activity, its function could be indirectly modulated by bortezomib. | ||||||
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $130.00 $270.00 | 37 | |
Vorinostat is an HDAC inhibitor, similar to Trichostatin A, altering gene expression by changing chromatin structure. SPINK11 expression could be indirectly affected by the broad changes in gene expression profile caused by vorinostat. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a multikinase inhibitor that targets RAF kinases, among others. Through inhibition of RAF and subsequent downstream effectors, sorafenib could indirectly impact SPINK11 expression or function. | ||||||